Evidence map›Paper›PMID 37936684›Full record

ArticleFrontiers in immunology2023

The effects of Phycocyanobilin on experimental arthritis involve the reduction in nociception and synovial neutrophil infiltration, inhibition of cytokine production, and modulation of the neuronal proteome.

Javier Marín-Prida, Arielis Rodríguez-Ulloa, Vladimir Besada, Alexey Llopiz-Arzuaga, Nathália Vieira Batista, Ignacio Hernández-González, Nancy Pavón-Fuentes, Érica Leandro Marciano Vieira, Viviana Falcón-Cama, Emilio F Acosta and 10 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Javier Marín-PridaCenter for Research and Biological Evaluations, Institute of Pharmacy and Food, University of Havana, Havana, Cuba.
Arielis Rodríguez-UlloaDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Vladimir BesadaDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Alexey Llopiz-ArzuagaDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Nathália Vieira BatistaLaboratory of Immunopharmacology, Department of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Ignacio Hernández-GonzálezDepartment of Non-Clinical Research, Isotopes Center, San José de Las Lajas, Mayabeque, Cuba.
Nancy Pavón-FuentesImmunochemical Department, International Center for Neurological Restoration (CIREN), Havana, Cuba.
Érica Leandro Marciano VieiraTranslational Psychoneuroimmunology Group, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
Viviana Falcón-CamaDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Emilio F AcostaDepartment of Characterization, Center for Advanced Studies of Cuba, Havana, Cuba.
Gillian Martínez-DonatoDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Majel Cervantes-LlanosDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Dai LingfengChina-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu Biotechnology Co. Ltd, Yongzhou, China.
Luis J GonzálezDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Julio Raúl Fernández-MassóDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Gerardo Guillén-NietoDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Eduardo Pentón-AriasDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Flávio Almeida AmaralLaboratory of Immunopharmacology, Department of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Mauro Martins TeixeiraLaboratory of Immunopharmacology, Department of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Giselle Pentón-RolDivision of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Centro de Ingeniería Genética y Biotecnología · CUUniversidade Federal de Minas Gerais · BRLatin American School of Medicine · CUInternational Center of Neurologic Restoration · CUUniversity of Havana · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The antinociceptive and pharmacological activities of C-Phycocyanin (C-PC) and Phycocyanobilin (PCB) in the context of inflammatory arthritis remain unexplored so far. In the present study, we aimed to assess the protective actions of these compounds in an experimental mice model that replicates key aspects of human rheumatoid arthritis. Methods: Antigen-induced arthritis (AIA) was established by intradermal injection of methylated bovine serum albumin in C57BL/6 mice, and one hour before the antigen challenge, either C-PC (2, 4, or 8 mg/kg) or PCB (0.1 or 1 mg/kg) were administered intraperitoneally. Proteome profiling was also conducted on glutamate-exposed SH-SY5Y neuronal cells to evaluate the PCB impact on this key signaling pathway associated with nociceptive neuronal sensitization. Results and discussion: C-PC and PCB notably ameliorated hypernociception, synovial neutrophil infiltration, myeloperoxidase activity, and the periarticular cytokine concentration of IFN-γ, TNF-α, IL-17A, and IL-4 dose-dependently in AIA mice. In addition, 1 mg/kg PCB downregulated the gene expression for T-bet, RORγ, and IFN-γ in the popliteal lymph nodes, accompanied by a significant reduction in the pathological arthritic index of AIA mice. Noteworthy, neuronal proteome analysis revealed that PCB modulated biological processes such as pain, inflammation, and glutamatergic transmission, all of which are involved in arthritic pathology. Conclusions: These findings demonstrate the remarkable efficacy of PCB in alleviating the nociception and inflammation in the AIA mice model and shed new light on mechanisms underlying the PCB modulation of the neuronal proteome. This research work opens a new avenue to explore the translational potential of PCB in developing a therapeutic strategy for inflammation and pain in rheumatoid arthritis.

Indexed as

Arthritis, ExperimentalArthritis, RheumatoidNeuroblastomaAnimalsCytokinesGene ExpressionHumansInflammationMiceMice, Inbred C57BLNeutrophil InfiltrationNociceptionPainPhycobilinsPhycocyaninProteomeCytokinesPhycobilinsPhycocyaninphycocyanobilinProteomeC-Phycocyaninglutamatergic transmissionhypernociceptioninflammationneutrophilsPhycocyanobilinproteomerheumatoid arthritis

Identifiers

PMID37936684
PMCPMC10627171
OpenAlexW4387869071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.